Lyophilized platelet rich plasma for the use in wound healing (chronic or acute) and bone or tissue grafts or repair

ABSTRACT

This invention relates to an improved Lyophilized platelet rich plasma used to make a platelet gel wound healant, and methods of preparation and use thereof for healing wounds are disclosed. The improved wound healant comprises therapeutically effective amounts of activated growth factors, platelet ghost, plasma (know as the plasma back bone), white blood cells with optional none, one or more additional anti-oxidant such as vitamin A and/or C and/or E, and/or none one or more antibiotics and/or GHK-Cu (produced by ProCyte Inc.)

FIELD OF TH INVENTION

This application is based on Provisional application No. 60/542,903Filed Feb. 9, 2004. The invention relates to an improved Lyophilizedplatelet rich plasma used to make a platelet gel wound healant, andmethods of preparation and use thereof for healing wounds are disclosed.The improved wound healant comprises a therapeutically effective amountof activated growth factors with optional none, one or more additionalanti-oxidant such as vitamin A and/or C and/or E, and/or one or moreantibiotics and/or GHK-Cu (produced by ProCyte Inc.).

The present invention relates to improved Lyophilized platelet richplasma for the use in wound healing and bone or tissue grafts andmethods of making and use thereof of Lyophilized or fixed platelets.

The present invention generally relates to the therapeutic uses of bloodplatelets and fresh plasma that has been combined and lyophilized, andmore particularly to manipulations or modifications of platelets andplasma, such as in preparing freeze-dried compositions that can berehydrated at the time of application and which when rehydrated have anormal response to thrombin and other agonists with respect to that offresh platelets. The inventive compositions are useful in applicationssuch as wound care.

PRIOR EFFORT OF OTHERS

Several techniques for preservation of platelets have been developedover the past few decades. Cryopreservation of platelets using variousagents, such as glycerol (Valeri et al., Blood, 43, 131-136, 1974) ordimethyl sulfoxide, “DMSO” (Bock et al., Transfusion, 35, 921-924,1995), as the cryoprotectant has been done with some success. The bestresults have been obtained with DMSO. However, a considerable fractionof these cells are partly lysed after thawing and have the shape of aballoon. These balloon cells are not responsive to various agonists, sothat overall responsiveness of frozen thawed platelets to variousagonists is reduced to less than 35% compared with fresh platelets. Theshelf life of cryopreserved DMSO platelets at −80.degree. C. is reportedto be one year, but requires extensive washing and processing to removecryoprotective agents, and even then the final product has a severereduction in ability to form a clot.

Attempts to dry platelets by Lyophilization have been described withparaformaldehyde fixed platelets (Read et al., Proc. Natl. Acad Sci.USA, 92, 397-401, 1995). U.S. Pat. No. 5,902,608, issued May 11, 1999,inventors Read et al. describe and claim a surgical aid comprising asubstrate on which fixed, dried blood platelets are carried. These driedblood platelets are fixed by contacting the platelets to a fixative suchas formaldehyde, paraformaldehyde, gutaraldehyde, or permanganate.Proper functioning of lyophilized platelets that have been fixed by suchfixative agents in hemostasis is questionable.

Spargo et al., U.S. Pat. No. 5,736,313, issued Apr. 7, 1998, hasdescribed a method in which platelets are loaded overnight with anagent, preferably glucose, and subsequently lyophilized. The plateletsare preincubated in a preincubation buffer and then are loaded withcarbohydrate, preferably glucose, having a concentration in the range ofabout 100 mM to about 1.5M. The incubation is taught to be conducted atabout 10.degree. C. to about 37.degree. C., most preferably about25.degree. C.

U.S. Pat. No. 5,827,741, Beattie et al., issued Oct. 27, 1998, disclosescryoprotectants for human platelets, such as dimethylsulfoxide andtrehalose. The platelets may be suspended, for example, in a solutioncontaining a cryoprotectant at a temperature of about 22.degree. C. andthen cooled to below 15.degree. C. This incorporates some cryoprotectantinto the cells.

Other workers have sought to load platelets with trehalose through useof electroporation before drying under vacuum. However, electroporationis very damaging to the cell membranes and is believed to activate theplatelets. Activated platelets have dubious clinical value.

Accordingly, a need exists for the effective and efficient preservationof platelets such that they maintain, or preserve, their biologicalproperties, particularly their response to platelet agonists such asthrombin, and which they release their growth factors. Further, it wouldalso be useful to expand the types of present vehicles that are usefulfor wound care.

There have been many different substances and methods developed in thepast for treating wounds, depending upon the type and location andseverity of the wound. A wound is generally defined as an injury to anarea of the body of a human or animal. Although injury to the surface ofthe skin is the most well known type of wound, the surfaces of internalorgans may also be wounded, such as during surgery, rupture of thespleen or liver, or resulting from traumatic blows to the body surfacein the vicinity of an internal organ.

Medical practice characterizes wounds as chronic or acute, according tothe persistence and severity of the wound. A chronic wound is one thatis prolonged or lingering, rather than promptly healed. An acute woundis one that occurs relatively quickly, and heals relatively quickly aswell. Tissue wounds may have a wide spectrum of manifestations, as smallas merely an abnormal microscopic tear or fissure in tissue (or asurface thereof), or as large as the abrasion or ablation of the skincovering a substantial portion of the body, such as in a burn victim.Acute wounds covering a large or movable surface are usually the mostdifficult to guard from infection, and to heal.

Blood and bodily fluids include various substances that affect woundhealing. The blood is the primary medium for delivering healing agentsto the wound site, and for transporting foreign or harmful substancesaway from the wound. Whole blood is primarily comprised of three maintypes of cells suspended in a protein rich solution known as plasma. Thethree main cell types in whole blood are erythrocytes (a.k.a. red bloodcells), leukocytes (a.k.a. white blood cells) and thrombocytes (a.k.a.platelets). The red blood cells are the iron-containing cells thatfacilitate the transport and transfer of oxygen to body tissue, and theremoval of carbon dioxide. The white blood cells perform a variety offunctions such as phagocytosis of foreign bodies and production ofantibodies, and are primarily responsible for fighting infection andforeign substances within the blood or wound site. Platelets performmany functions such as plugging leaks in blood vessels and helping beginthe process leading to the formation of a blood clot; platelets containsubstances known as growth factors that facilitate the formation of newtissue.

Although there are several methods for separating whole blood into itsvarious components, one of the most convenient and expeditious methodsis accomplished by differentially centrifuging blood or some of itscomponents (i.e., apheresis). Using apheresis, the red and white bloodcells and plasma may be separated out and returned to the donor's orpatient's body, leaving the sequestered platelets in essentiallyconcentrated form for use in wound healing techniques. This may bepreformed at a blood collection center, blood bank, at the PhysiciansClinic or Hospital. From blood extracted from a patient or from theother forms of collection methods, the platelets may thus be obtainedand activated for use on the patient; methods of using a patient's ownblood are called “autologous” or “autogenic” donor methods. Anothermethod using blood donated by one or more third parties for use by apatient are called “homologous” or “heterologous” donor methods, orcollectively called “allogenic” methods.

One of the proteins suspended in plasma is fibrinogen, which reacts withsubstances released into (or attracted by) wound sites to produce stickystrands of fibrin. Such reactions result in the cross linking of thefibrin strands to form a mesh that holds and supports the deposit orgrowth of other tissue materials at the wound site. Therefore, the needfor fresh plasma also known in the art “The Plasma Back Bone”.

The wound healing process is generally considered to occur in severalstages, generally known as the healing cascade. After tissue injury,platelets are among the first cells to appear in the vicinity of thewound. Activation of a platelet by an agonist such as thrombin, or otheragonists such as those listed elsewhere herein, leads to the release ofgranule material from within the platelet. Such granulation activationresults in the release of proteins known as growth factors, primarilyconcentrated in the alpha granules of platelets. These released growthfactors stimulate the formation of new tissue; when applied to wounds,growth factors have been known to increase the rate of collagen laydown,vascular ingrowth, fibroblast proliferation and overall healing. Therelease of a protein known as platelet-derived growth factor (PDGF) is achemotactic signal for monocytes, neutrophils and fibroblasts, whichthen move into the wound, to begin the inflammatory stage of the healingprocess. During this time, monocytes secrete a number of factorsincluding PDGF and transforming growth factor-.beta. 1 (also found inplatelets), which recruits and activates fibroblasts, to begin therepair stage of the healing process. Subsequently, wound healingcontinues through the process of collagen remodeling within the wound.Thus the importance of the ability of the Lyophilized platelet richplasma to release their growth factors.

Based upon the foregoing general scientific principles, already known inthe field are wound sealants made from biological materials obtainedprimarily from tissue other than blood platelets. An example is woundsealants such as “fibrin glue”, which often are essentially a mixture ofco-coagulants (thrombin and calcium), concentrated fibrinogen and othercoagulation proteins. In most applications, the primary roles of fibringlue are to seal wound surfaces to prevent loss of blood and other bodyfluids after surgery, and to provide adhesion between adjacent tissuesurfaces. These products form a hard, cast-like covering over the areato be sealed, and tend to be non-yielding to limb movement.

While there has been much research concerning fibrin glue, this materialbelongs to a separate field from the present invention, primarilybecause fibrin glues typically contain cryoprecipitated proteins withoutplatelets. The use of fibrin glue is discussed extensively in thescientific literature; for example, see the references cited in U.S.Pat. No. 5,585,007 issued to Antanavich et al on Dec. 17, 1996.

Wound treatment compositions derived from platelet enriched concentratesare known and possess certain advantages over materials withoutplatelets such as fibrin glue. One reason is that natural wound healingagents are released by the platelets. Further, the concentration ofplatelets likewise allows for a concentrated amount of wound healingfactors. Representative examples of platelet derived wound treatmentcompositions are described for instance in Hood U.S. Pat. No. 5,733,545;Knighton U.S. Pat. No. 5,165,938; and Gordiner U.S. Pat. No. 5,599,558.This form of treatment has major problems, like time consuming andproblems collecting blood sometimes with expensive machines anddisposables.

Platelet concentrates are typically isolated by the process ofdifferential centrifugation, which essentially allows separating theblood into at least three different components: packed erythrocytes (redblood cells), plasma and platelet concentrate. Platelet concentrate canbe combined with a solution of either sodium or calcium mixed withthrombin (“calcified thrombin”), which instantaneously form acomposition of activated platelets that, when made with the necessaryviscosity, can be utilized as a wound sealant. The chemical reactionsand cascades that normally occur when thrombin is added to theconcentrated platelets are indeed complex. See, for instance, Reeder, etal, in Proceedings of the American Academy of Cardiovascular Perfusion,Vol. 14, January 1993. Such wound sealants typically set up into a hardmass covering the application site, thereby sealing the site againstfurther blood loss and external contaminants.

There are a number of disadvantages associated with conventional woundcompositions derived from platelet concentrates. For instance,activation of platelets leads to instantaneous hardening of the materialand thus requires the physician to both activate and apply the plateletcomposition to the wound site within seconds of activation. Also,certain platelet compositions must be applied to the wound site on adaily basis and thus require regular blood withdrawal from the patient.This is time consuming and if more of the compositions is needed, thenanother needle stick is needed and the process time required to make thecomposition.

Accordingly, an improved Lyophilized platelet enriched plasma woundtreatment composition which avoids or diminishes the problems associatedwith typical platelet enriched wound compositions and would bedesirable.

SUMMARY OF THE INVENTION

In one aspect of the present invention, a dehydrated composition isprovided comprising freeze-dried platelets and fresh plasma that areeffectively to preserve biological properties during freeze-drying andrehydration. These platelets are rehydratable so as to have a normalresponse to at least one agonist, such as thrombin. For example,substantially all freeze-dried platelets of the invention whenrehydrated and mixed with thrombin (1 U/ml) form a clot within threeminutes at 37.degree. C. The dehydrated composition can include one ormore other agents, such as antibiotics, antifungals, growth factors, orthe like, depending upon the desired therapeutic application.

The present invention relates to an improved Lyophilized platelet andplasma composition for wound treatment, a method of making and usethereof. The composition comprises Lyophilized platelets and plasmacomposition in liquid form to the wound site and will gel to prevent thematerial from flowing away from the site. Optional antibiotics may beincluded in the improved composition to prevent infections at the woundsite. The presence of the anti-oxidant, including vitamins andnon-vitamin anti-oxidants, and other healing promotion materials that donot detract from, substantially interfere with, or even destroy thedifferent thrombin activation reactions. The inventive Lyophilizedplatelet gels containing fresh plasma is prepared for topicalapplication at the wound site and avoid the requirement for dailyreapplication.

Methods of making and using inventive embodiments are also described.One such method is a process of preparing a dehydrated compositioncomprising providing a source of platelets and fresh plasma andlyophilizing the platelets and plasma. The rehydration preferably donewith de-ionized water.

While the inventive composition is preferably used for topicalapplication to the exterior surface of the chronic wounds such as ulcersof the feet of diabetics, the composition may be applied to facilitatethe healing of other wounds such as acute wounds such as surgery burns.However, the composition of matter and the methods described herein arenot limited solely to topical application.

The inventive composition increases the amount of growth factors in thewound, and thereby facilitates the promotion of the healing rate. Thismay be especially important in “wounded” patients, especially those withchronic wounds who may lack sufficient circulation to facilitate thehealing cascade. The invention described herein also facilitates thecovering of the wound area with a substance that prevents or helps toreduce infection caused by most bacteria;

Practice of the invention permits the manipulation or modification ofplatelets and plasma while maintaining, or preserving, biologicalproperties, such as a response to thrombin. The inventive freeze-driedplatelets and plasma including the freeze-dried platelets, aresubstantially shelf stable at ambient temperatures when packaged inmoisture barrier materials.

In most general terms, the invention described herein expands the usesfor concentrated platelet materials, especially those in gel form, byimproving the speed and convenience of making the composition; theinvention described herein also improves the performance of theconcentrated platelet composition, by making it more useable forapplications over longer periods of time, and by enhancing the woundhealing and infection fighting properties.

Another aspect of the present invention involves adding one or moreantibiotic substance at one or more times during the processing periodso that the resulting concentrated platelet and plasma compositioncontains either one or a variety of the antibiotics. The use of anantibiotic in concentrated platelet and plasma compositions thatenhances the complex healing cascade is indeed novel. The inventiondisclosed herein involves adding such substances in a manner that doesnot detract from, substantially interfere with, or even destroy thesedifferent reactions, pH balances and potency.

Another aspect of the present invention involves adding one or morevitamins, to the concentrated platelet gel. Vitamins are known to havewound healing and anti-oxidant properties. Representative examples ofsuitable, but none limiting, vitamins include vitamin E, vitamin A,vitamin C and other retinoids.

In yet another aspect of the invention, non-vitamin anti-oxidants may beincluded in the concentrated platelet gel. Non-limiting representativeexamples of such anti-oxidants include beta-carotene.

DETAILED DESCRIPTION OF THE INVENTION

For the sake of simplicity and to give the claims of this patentapplication the broadest interpretation and construction possible, thefollowing definitions will apply:

(a) The phrase blood collecting or blood extraction (or similar phrase)includes techniques, materials and apparatus known in the field, such as(for example) inclusion of anticoagulation materials, the use of blooddrawing and infusion apparatus.

(b) the phrase growth factor means any material(s) promoting growth of atissue.

(c) The term thrombin may include calcified thrombin, in particular,about 5,000 units of thrombin per 5 ml of 10% of aqueous calciumchloride solution; it may include calcified bovine thrombin as well asautologous thrombin, allogeneic thrombin or recombinant human thrombin.

(d) The term viscosity means those characteristics of the specifiedmaterial(s) determining the degree of gelation, such as (for example)the firmness or hardness of the material, or the degree to which thematerial resists flowing like a fluid.

(e) The term therapeutically effective amount means the amount oramounts of the constituent elements or combination thereof necessary toenhance wound healing such as, for example, the reduction in the volumeor surface area of a wound, the increase in the amount of granulationtissue or other biological material facilitating collagen laydown,vascular ingrowth, fibroblast proliferation or overall healing; all ofthe versions of the invention described herein are assumed to have thetherapeutically effect amount(s) of constituent substances, orcombinations thereof.

(f) the term anti-oxidant refers to any material(s) having anti-oxidantproperties. Anti-oxidant would include, without limitation, vitaminssuch as vitamins C, A and E and non-vitamins such as -carotene.

Also for the sake of simplicity, the conjunctive “and” may also be takento include the disjunctive “or”, and vice versa, whenever necessary togive the claims of this patent application the broadest interpretationand construction possible. Likewise, when the plural form is used it maybe taken to include the singular form and vice versa.

In most general terms, the invention includes a wound healantcomposition comprising activated growth factors and ascorbic acid. Inthe prevalent version of the invention, said growth factors are includedwithin platelets. The body produces many substances generally known asgrowth factors, and these growth factors are contemplated for use in thepresent invention. The preferred growth factors for use in the presentinvention are selected from the group consisting of platelet-derivedgrowth factor (PDGF), platelet-derived angiogenesis factor (PDAF),vascular endotheial growth factor (VEGF), platelet-derived epidermalgrowth factor (PDEGF), platelet factor 4 (PF-4), transforming growthfactor .beta. (TGF-B), acidic fibroblast growth factor (FGF-A), basicfibroblast growth factor (FGF-B), transforming growth factor alpha.(TGF-A), insulin-like growth factors 1 and 2 (IGF-1 and IGF-2), beta.thromboglobulin-related proteins (BTG), thrombospondin (TSP),fibronectin, von Wallinbrand's factor (vWF), fibropeptide A, fibrinogen,albumin, plasminogen activator inhibitor 1 (PAI-1), osteonectin,regulated upon activation normal T cell expressed and presumablysecreted (RANTES), gro-.alpha., vitronectin, fibrin D-dimer, factor V,antithrombin III, immunoglobulin-G (IgG), immunoglobulin-M (IgM),immunoglobulin-A (IgA), a2-macroglobulin, angiogenin, Fg-D, elastase,keratinocyte growth factor (KGF), epidermal growth factor (EGF),fibroblast growth factor (FGF), tumor necrosis factor (TNF), fibroblastgrowth factor (FGF) and interleukin-1 (IL-1), Keratinocyte GrowthFactor-2 (KGF-2). and combinations thereof One of the importantcharacteristics common to each substance, supporting the inclusion ofeach in this particular group, is that each such substance is known orbelieved to enhance cell or tissue growth. Moreover, said substances, orvarious combinations thereof, are known or believed to function togetherin an unexpected synergistic manner to promote wound healing. Suitable,non-limiting, anti-oxidants useful in the invention include but are notlimited to vitamins such as vitamin C (ascorbic acid), vitamin E,vitamin A and other retinoids; and the carotenes such as beta.-carotene.In practicing this invention, ascorbic acid as anti-oxidant isparticularly preferred.

The platelets are separated from the red blood cells and white bloodcells of whole blood, primarily through differential centrifugation,although any suitable method for separating platelets from whole bloodmay be employed in practicing this invention. The overall composition ofthe invention disclosed herein may contain incidental amounts of whiteblood cells, due to the fact that the platelets are rarely totallyisolated from the other blood components. It is believed that thepresent invention contains only minimal or trace amounts of white bloodcells; it is believed that the white blood cell count of the presentinvention typically will be below about 3 times 10.sup.7 cell/ml. Thebioactive material in the invention is almost exclusively fromplatelets. The range of the mean platelet volume of the platelets beingsequestered is in the range of about 6.6 to 8.4 femtoliters, with anaverage of about 7.7 femtoliters; this may indicate that the plateletsbeing sequestered are relatively larger or younger than the overallpopulation of platelets.

Activation of growth factors may occur in a variety of manners, by avariety of substances known as activators or agonists. In the inventiondescribed herein, said activation results from lysine and the inclusionof an activator or agonist selected from the group consisting ofthrombin, glass, collagen, serotonin, adenosine diphosphate (ADP) andacetylcholine (ACH), and combinations thereof. In a particular andpreferred version of the invention, said growth factors are includedwithin concentrated platelets, and said activation results from theinclusion of thrombin. One of the important characteristics common toeach substance, supporting the inclusion of each in this particulargroup, is that each such substance is known or believed to enhance cellor tissue growth in addition to the ability to activate platelets.Moreover, said substances, or various combinations thereof, are known orbelieved to function together in an unexpected synergistic manner topromote wound healing.

The activator or agonist added to the platelet and plasma concentrate isin an amount sufficient to facilitate the formation of the coagulum(gel) having a predetermined viscosity while sufficiently activatinggrowth factors present in the composition. In the preferred case wherethrombin is employed as the activator to produce a final soft gel woundcomposition in a soft gel form, the amount of thrombin generally rangesbetween about 100 U and about 10,000 U, preferably about 900 U and about1100 U, most preferably about 1000 U per 10 cc of platelet concentrate.Thrombin is available as Thrombogen.RTM. thrombin, topical USP (bovineorigin) in vials containing 5000 units thrombin (Johnson & JohnsonMedical Inc., Arlington, Tex., USA).

Since the admixture of thrombin or other agonists will activate growthfactors, the thrombin (or other agonists/activators) should usually bethe last substance to be mixed immediately before it is desired that thegelatinous state be set up.

Besides a method of making a wound healant composition, the inventiondescribed herein may also include a method of treating a wound,comprising the steps of applying a sufficient amount of a composition ofmatter comprising growth factors to enhance healirig of the wound. Saidmethod of treating a wound may include the use of any of thecompositions described herein; it may also include the use of anycomposition made by any of the methods described herein.

Once applied to a wound, the composition may remain on the wound for aslong as 5 days, and perhaps longer depending upon the circumstances suchas the location of the wound and other wound characteristics. Althoughthe composition and method described herein are especially useful forthe treatment of chronic wounds, they may also be useful in thetreatment of acute wounds.

EXAMPLE 1

Preparation of Lyophilized Platelet Rich Plasma for the use in WoundHealing (Chronic or Acute) and Bone or Tissue Grafts.

(a) The First Method for Human blood components obtained from a bloodbank or collection center:

The components needed:

1. Pooled or single donor platelets (containing at least 5×10 to the 9thplatelets) about 40 ml to 50 ml per bag.

2. Pooled or single donor fresh frozen plasma (about 250 ml) per bag.

3. Centrifuge with the capabilities of spinning 50 ml tubes up to 5000rpms.

4. 50 ml tubes.

5. Pipettes from 0.01 ul to 50 ml

6. Vials with stoppers and caps.

Method:

1. Remove the platelets from the bag and place in a 50 ml tube andcentrifuge for 15-20 min. at 5000 rpms to form a platelet plug, which isknown in the art.

2. Remove and discard the platelet poor plasma from the tube ofplatelets.

3. Thaw the fresh frozen plasma ad insert an amount into the plateletplug container as to cause a platelet count of between 250,000 to4,500,000 platelets per milliliter. Being very careful that the freshPlasma does not stay thawed for more than 4 hours.

4. Gently rotate back and forth to cause the platelets and plasma to mixwell.

5. Pipette the desired amount of PRP into the vials to be lyophilizedand place the stoppers in place.

6. Lyophilize at once (take care as to not allow any warming to occur).

7. The first cycle should be for 48 hours.

8. The second cycle should be for 12 hours.

For this example 10 ml of the PRP was Lyophilized and capped.

To apply to the wound using the 10 ml vials of LPRP:

a. Rehydrate using (10 ml) de-ionized water and allow to stand for atleast 10 to 15 minutes.

b. Remove the LPRP using a 20 ml syringe.

c. Add 1 ml of Thrombin (bovine) 1000 u per milliliter

d. Place on the wound and cover with a moist gauze.

e. Cover the wound with an exclusive dressing.

f. Allow too stay in place for 4 to 7 days without changing thedressing.

g. Repeat if necessary.

EXAMPLE 2

(a) The Second Method for Human blood components obtained from a bloodbank or collection center:

The components needed:

1. Pooled or single donor platelets (containing at least 5×10 to the 9thplatelets) about 40 ml to 50 ml per bag.

2. Pooled or single donor fresh frozen plasma (about 250 ml) per bag.

3. Centrifuge with the capabilities of spinning 50 ml tubes up to 5000rpms.

4. 50 ml tubes.

5. Pipettes from 0.01 ul to 50 ml

6. Vials with stoppers and caps.

7. GHK-Cu ranging from 0.02 mg/ml to 0.5 mg/ml in liquid form

Method:

1. Remove the platelets from the bag and place in a 50 ml tube andcentrifuge for 15-20 min. at 5000 rpms to form a platelet plug, which isknown in the art.

2. Remove and discard the platelet poor plasma from the tube ofplatelets.

3. Thaw the fresh frozen plasma ad insert an amount into the plateletplug container as to cause a platelet count of between 250,000 to4,500,000 platelets per milliliter. Being very careful that the freshPlasma does not stay thawed for more than 4 hours.

4. Add an amount of GHK-Cu to equal 1 ml per 9 ml of LPRP

5. Gently rotate back and forth to cause the platelets and plasma to mixwell.

6. Pipette the desired amount of PRP into the vials to be lyophilizedand place the stoppers in place.

7. Lyophilize at once (take care as to not allow any warming to occur).

8. The first cycle should be for 48 hours.

9. The second cycle should be for 12 hours.

For this example 10 ml of the PRP was Lyophilized and capped.

To apply to the wound using the 10 ml vials of LPRP:

a. Re-hydrate using (10 ml) de-ionized water and allow to stand for atleast 10 to 15 minutes.

b. Remove the LPRP using a 20 ml syringe.

c. Add 1 ml of Thrombin (bovine) 1000 u per milliliter

d. Place on the wound and cover with a moist gauze.

e. Cover the wound with an exclusive dressing.

f. Allow too stay in place for 4 to 7 days without changing thedressing.

g. Repeat if necessary.

(b) The Third Method for Human blood components obtained from a bloodbank or collection center:

The components needed:

1. Pooled or single donor platelets (containing at least 5×10 to the 9thplatelets) about 40 ml to 50 ml per bag.

2. Pooled or single donor fresh frozen plasma (about 250 ml) per bag.

3. Centrifuge with the capabilities of spinning 50 ml tubes up to 5000rpms.

4. 50 ml tubes.

5. Pipettes from 0.01 ul to 50 ml

6. Vials with stoppers and caps.

7. GHK-Cu ranging from 0.02 mg/ml to 0.5 mg/ml gauze

Method:

1. Remove the platelets from the bag and place in a 50 ml tube andcentrifuge for 15-20 min. at 5000 rpms to form a platelet plug, which isknown in the art.

2. Remove and discard the platelet poor plasma from the tube ofplatelets.

3. Thaw the fresh frozen plasma ad insert an amount into the plateletplug container as to cause a platelet count of between 250,000 to4,500,000 platelets per milliliter. Being very careful that the freshPlasma does not stay thawed for more than 4 hours.

4. Gently rotate back and forth to cause the platelets and plasma to mixwell.

5. Pipette the desired amount of PRP into the vials to be lyophilizedand place the stoppers in place.

6. Lyophilize at once (take care as to not allow any warming to occur).

7. The first cycle should be for 48 hours.

8. The second cycle should be for 12 hours.

For this example 10 ml of the PRP was Lyophilized and capped.

To apply to the wound using the 10 ml vials of LPRP:

a. Re-hydrate using (10 ml) de-ionized water and allow to stand for atleast 10 to 15 minutes.

b. Remove the LPRP using a 20 ml syringe.

c. Add 1 ml of Thrombin (bovine) 1000 u per milliliter

d. Place on the wound and cover with GHK-Cu gauze.

e. Cover the wound with an exclusive dressing.

f. Allow too stay in place for 4 to 7 days without changing thedressing.

g. Repeat if necessary.

(c) The Forth Method for Human blood components obtained from a bloodbank or collection center:

The components needed:

1. Pooled or single donor platelets (containing at least 5×10 to the 9thplatelets) about 40 ml to 50 ml per bag.

2. Pooled or single donor fresh frozen plasma (about 250 ml) per bag.

3. Centrifuge with the capabilities of spinning 50 ml tubes up to 5000rpms.

4. 50 ml tubes.

5. Pipettes from 0.01 ul to 50 ml

6. Vials with stoppers and caps.

7. Vitamin C is an amount equal to 10%

Method:

1. Remove the platelets from the bag and place in a 50 ml tube andcentrifuge for 15-20 min. at 5000 rpms to form a platelet plug, which isknown in the art.

2. Remove and discard the platelet poor plasma from the tube ofplatelets.

3. Thaw the fresh frozen plasma ad insert an amount into the plateletplug container as to cause a platelet count of between 250,000 to4,500,000 platelets per milliliter. Being very careful that the freshplasma does not stay thawed for more than 4 hours.

4. Add an amount of Vitamin C to equal 1 ml per 9 ml of LPRP

5. Gently rotate back and forth to cause the platelets and plasma to mixwell.

6. Pipette the desired amount of PRP into the vials to be lyophilizedand place the stoppers in place.

7. Lyophilize at once (take care as to not allow any warming to occur).

8. The first cycle should be for 48 hours.

9. The second cycle should be for 12 hours.

For this example 10 ml of the PRP was Lyophilized and capped.

To apply to the wound using the 10 ml vials of LPRP:

a. Re-hydrate using (10 ml) de-ionized water and allow to stand for atleast 10 to 15 minutes.

b. Remove the LPRP using a 20 ml syringe.

c. Add 1 ml of Thrombin (bovine) 1000 u per milliliter

d. Place on the wound and cover with a moist gauze.

e. Cover the wound with an exclusive dressing.

f. Allow too stay in place for 4 to 7 days without changing thedressing.

g. Repeat if necessary.

(d) The Fifth Method for Human blood components obtained from a bloodbank or collection center:

The components needed:

1. Pooled or single donor platelets (containing at least 5×10 to the 9thplatelets) about 40 ml to 50 ml per bag.

2. Pooled or single donor fresh frozen plasma (about 250 ml) per bag.

3. Centrifuge with the capabilities of spinning 50 ml tubes up to 5000rpms.

4. 50 ml tubes.

5. Pipettes from 0.01 ul to 50 ml

6. Vials with stoppers and caps.

7. Vitamin C is an amount equal to 10%

Method:

1. Remove the platelets from the bag and place in a 50 ml tube andcentrifuge for 15-20 min. at 5000 rpms to form a platelet plug, which isknown in the art.

2. Remove and discard the platelet poor plasma from the tube ofplatelets.

3. Thaw the fresh frozen plasma ad insert an amount into the plateletplug container as to cause a platelet count of between 250,000 to4,500,000 platelets per milliliter. Being very careful that the freshPlasma does not stay thawed for more than 4 hours.

4. Gently rotate back and forth to cause the platelets and plasma to mixwell.

5. Pipette the desired amount of PRP into the vials to be lyophilizedand place the stoppers in place.

6. Lyophilize at once (take care as to not allow any warming to occur).

7. The first cycle should be for 48 hours.

8. The second cycle should be for 12 hours.

For this example 10 ml of the PRP was Lyophilized and capped.

To apply to the wound using the 10 ml vials of LPRP:

a. Re-hydrate using (10 ml) de-ionized water and allow to stand for atleast 10 to 15 minutes.

b. Remove the LPRP using a 20 ml syringe.

c. Add 1 ml of Thrombin (bovine) 1000 u per milliliter

d. Add 1 ml of 10% Vitamin C, A.K.A. (Ascorbic Acid)

e. Place on the wound and cover with a moist gauze.

f. Cover the wound with an exclusive dressing.

g. Allow too stay in place for 4 to 7 days without changing thedressing.

h. Repeat if necessary.

(e) The sixth Method for Human blood components obtained from a bloodbank or collection center:

The components needed:

1. Pooled or single donor platelets (containing at least 5×10 to the 9thplatelets) about 40 ml to 50 ml per bag.

2. Pooled or single donor fresh frozen plasma (about 250 ml) per bag.

3. Centrifuge with the capabilities of spinning 50 ml tubes up to 5000rpms.

4. 50 ml tubes.

5. Pipettes from 0.01 ul to 50 ml

6. Vials with stoppers and caps.

7. Vitamin C is an amount equal to 10%

8. GHK-Cu ranging from 0.02 mg/ml to 0.5 mg/ml in liquid form

Method:

1. Remove the platelets from the bag and place in a 50 ml tube andcentrifuge for 15-20 min. at 5000 rpms to form a platelet plug, which isknown in the art.

2. Remove and discard the platelet poor plasma from the tube ofplatelets.

3. Thaw the fresh frozen plasma ad insert an amount into the plateletplug container as to cause a platelet count of between 250,000 to4,500,000 platelets per milliliter. Being very careful that the freshPlasma does not stay thawed for more than 4 hours.

4. Add an amount of Vitamin C to equal 0.05 ml to 1 ml per 9 ml of LPRP

5. Add an amount of GHK-Cu to equal 0.05 ml to 1 ml per 9 ml of LPRP

6. Gently rotate back and forth to cause the platelets and plasma to mixwell.

7. Pipette the desired amount of PRP into the vials to be lyophilizedand place the stoppers in place.

8. Lyophilize at once (take care as to not allow any warming to occur).

9. The first cycle should be for 48 hours.

10. The second cycle should be for 12 hours.

For this example 10 ml of the PRP was Lyophilized and capped.

To apply to the wound using the 10 ml vials of LPRP:

a. Re-hydrate using (10 ml) de-ionized water and allow to stand for atleast 10 to 15 minutes.

b. Remove the LPRP using a 20 ml syringe.

c. Add 1 ml of Thrombin (bovine) 1000 u per milliliter

d. Place on the wound and cover with a moist gauze.

e. Cover the wound with an exclusive dressing.

f. Allow too stay in place for 4 to 7 days without changing thedressing.

g. Repeat if necessary.

EXAMPLE 3

(a) The sixth method for human or animal, obtained from apheresis either

Autologous or Homologous:

The components needed:

1. Single donor platelets (obtained from apheresis) about 40 ml to 50 mlper bag.

2. Centrifuge with the capabilities of spinning 50 ml tubes up to 5000rpms.

3. 50 ml tubes.

4. Pipettes from 0.01 ul to 50 ml.

5. Vials with stoppers and caps.

Method:

1. Remove the platelets from the bag of apheresis platelets.

2. Add fresh plasma into the platelets in an amount to cause a plateletcount of between 250,000 to 4,500,000 platelets per milliliter. Beingvery careful that the fresh platelet rich plasma does not stay thawedfor more than 6 hours.

3. Gently rotate back and forth to cause the platelets and plasma to mixwell. 4. Pipette the desired amount of PRP into the vials to belyophilized and place the stoppers in place.

5. Lyophilize at once (take care as to not allow any warming to occur).

6. The first cycle should be for 48 hours.

7. The second cycle should be for 12 hours.

For this example 10 ml of the PRP was Lyophilized and capped.

To apply to the wound using the 10 ml vials of LPRP:

a. Re-hydrate using (10 ml) de-ionized water and allow to stand for atleast 10 to 15 minutes.

b. Remove the LPRP using a 20 ml syringe.

c. Add 1 ml of Thrombin (bovine) 1000 u per milliliter

d. Place on the wound and cover with a moist gauze.

e. Cover the wound with an exclusive dressing.

f. Allow too stay in place for 4 to 7 days without changing thedressing.

g. Repeat if necessary.

EXAMPLE 4

(c) The third method for human blood components obtained from a bloodbank and activated prior to Lyophilization with Thrombin (bovine orintrinsic):

The components needed:

1. Pooled or single donor platelets (containing at least 5×10 to the 9thplatelets) about 40 ml to 50 ml per bag.

2. Pooled or single donor fresh frozen plasma (about 250 ml) per bag.

3. Centrifuge with the capabilities of spinning 50 ml tubes up to 5000rpms.

4. 50 ml tubes.

5. Pipettes from 0.01 ul to 50 ml Vials with stoppers and caps.

6. Thrombin and Calcium Chloride or Glass Beads or Glass Wool.

Method:

1. Remove the platelets from the bag and place in a 50 ml tube andcentrifuge for 15-20 min. at 5000 rpms to form a platelet plug, which isknown in the art.

2. Remove and discard the platelet poor plasma from the tube ofplatelets.

3. Remove 50% of the platelet plug and activate the plug with Thrombinor pass the platelets through either glass wool or glass beads and allowactivated platelets to rest for about 15 min. then centrifuge for 15min. and remove the serum with out the plug. Then pipette equal amountsof the serum into the vials in equal amounts.

4. Thaw the fresh frozen plasma and insert an amount into the plateletplug container as to cause a platelet count of between 250,000 to4,500,000 platelets per milliliter. Being very careful that the freshPlasma does not stay thawed for more than 4 hours.

5. Gently rotate back and forth to cause the platelets and plasma to mixwell.

6. Pipette the desired amount of PRP into the vials to be lyophilizedand place the stoppers in place.

7. Lyophilize at once (take care as to not allow any warming to occur).

8. The first cycle should be for 48 hours.

9. The second cycle should be for 12 hours.

For this example 10 ml of the PRP was Lyophilized and capped.

To apply to the wound using the 10 ml vials of ALPRP:

h. Rehydrate using (10 ml) de-ionized water and allow to stand for atleast 10 to 15 minutes.

i. Remove the LPRP using a 20 ml syringe.

j. Place on the wound and cover with a moist gauze.

k. Cover the wound with an exclusive dressing.

l. Allow too stay in place for 4 to 7 days without changing thedressing.

m. Repeat if necessary.

1. A dehydrated composition, useful for mammalian therapy, comprising:substantially shelf-stable freeze-dried platelets selected from themammalian species for which therapy is intended, the platelets beingeffectively loaded with fresh or fresh frozen plasma Less than 6 hoursold for biological properties during freeze-drying and rehydration,wherein the platelets are rehydratable so as to have a normal responseto at least one agonist.
 2. The method of claim 1 wherein saidcomposition is lyophilized.
 3. The method of claim 2 where in saidcomposition is frozen to −50° C. for 4 hours and −20° C. for theduration of the procedure and not allowing to warm up above −20° C.during the entire process of Lyophilization.
 4. The method of claim 2where said composition is lyophilized for 24 to 60 hours.
 5. A woundhealant described in claim 1, wherein said lyophilized activatedplatelet and plasma concentrate results from the inclusion of an agonistto activate a platelet and plasma concentrate.
 6. A wound healantdescribed in claim 5, wherein said agonist is selected from the groupconsisting of thrombin, glass, collagen, serotonin, adenosinediphosphate (ADP) and acetylcholine (ACH), and combinations thereof. 7.A wound healant described in claim 1, wherein said growth factors areincluded within concentrated platelets and plasma, and said activationresults from the inclusion of thrombin and the act of lysine as a resultof Lyophilization.
 8. A wound healant described in claim 7, wherein saidconcentrated platelets are autologous or homologous concentratedplatelets and having a white blood cell count of below about 3 time10.sup.7 cells/ml.
 9. A wound healant composition comprising atherapeutically effective amount of concentrated Lyophilized platelets,plasma and/or growth factors and/or thrombin.
 10. A wound healantcomposition comprising a therapeutically effective amount ofconcentrated Lyophilized platelets, plasma, at least one anti-oxidantand thrombin.
 11. A wound healant composition described in claim 10,wherein said anti-oxidant comprises a retinoid, vitamin E, C, A orbeta-carotene.
 12. A wound healant composition described in claim 11,wherein said retinoid is vitamin A.
 13. A wound healant compositioncomprising a therapeutically effective amount of concentratedLyophilized platelets, plasma, at least one antibiotic and thrombin. 14.A wound healant described in claim 13, wherein said antibiotic isbacteriocidal to at least Pseudomonas and Klebsella bacteria.
 15. Awound healant described in claim 14, wherein said antibiotic is selectedfrom the group consisting of a neosporin, vancomycin and gentamycin, andcombinations thereof
 16. A wound healant composition comprising atherapeutically effective amount of concentrated Lyophilized platelets,plasma, and GHK-Cu produced by ProCyte Inc. of Seattle, Wash.
 17. Awound healant composition comprising concentrated lyophilized platelets,plasma, at least one retinoid, at least one antibiotic bacteriocidal toat least Pseudomonas and Klebsella and thrombin.
 18. A wound healantcomposition comprising concentrated platelets in an amount rangingbetween about 250,000 and about 2.times. 10.sup.9 cells/ml, vitamin C,thrombin in an amount ranging between about 100 U and about 10,000 U,preferably about 900 U and about 1100 U, most preferably about 1000 Uper 10 cc of platelet concentrate and calcium chloride in an amountranging between about 0.1 mg/ml and about 10 mg/ml. Or passed through apiece of glass (i.e. glass wool or glass beads both uncoated).
 19. Awound healant composition as described in claim 18, further comprisingvitamin A and vitamin E in effective anti-oxidative amounts.
 20. Amethod of making a wound healant composition, comprising the steps ofmixing, in therapeutically effective amount(s), activated Lyophilizedplatelet and plasma concentrate.
 21. A method of making a wound healantdescribed in claim 20, wherein said activated Lyophilized platelet andplasma concentrate are obtained from a blood bank or collection centeror Apheresis and mixing thrombin with said platelets.
 22. A method ofmaking a wound healant described in claim 20, said method furthercomprising, either prior to or after Lyophilization and mixing at leastone retinoid in sufficient amount(s) to further enhance wound healing.23. A method of making a wound healant described in claim 20, saidmethod further comprising, prior to mixing said thrombin, mixing atleast one antibiotic in sufficient amount(s) to reduce infection bybacteria.
 24. A method of making a wound healant described in claim 23,wherein said antibiotic is at least bacteriocidal to Pseudomonas andKlebsella bacteria.
 25. A method of making a wound healant described inclaim 23, wherein said antibiotic is selected from the group consistingof neosporin, vancomycin and gentamycin, and combinations thereof.
 26. Amethod of making a wound healant, comprising the steps of, prior to orafter Lyophilization, admixing, in therapeutically effective amount(s),concentrated platelets, ascorbic acid, at least one retinoid and atleast one antibiotic bacteriocidal to at least Pseudomonas and Klebsellabacteria.
 27. A method of making a wound healant composition, comprisingthe steps of: extracting blood from a patient, through Apheresis saidblood until the appearance of an essentially separate of plasma, anessentially separate of red blood cells, and an essentially intermediategrouping comprised of concentrated platelets and plasma there between;removing said plasma band; centrifuging said remaining blood componentsat said speed an sufficient duration; removing said concentratedplatelets; and mixing, in therapeutically effective amount(s), saidconcentrated platelets with plasma and thrombin and then Lyophilizingeither before adding thrombin or after adding thrombin.
 28. A woundhealant prepared in accordance with claims 20-27.
 29. A wound healantprepared in accordance with claim
 26. 30. A wound healant prepared inaccordance with claim 27.